GLIA Diagnostics: Point of Care Concussion Diagnostics (Testing for TBI - Traumatic Brain Injury)
GLIA Diagnostics Pty Ltd, D+I, Melbourne Centre for Nanofabrication (MCN), and Alfred Hospital are working with the CSIRO in the development of a Traumatic Brain Injury (TBI) diagnostic point of care device which uses finger-stick testing methods to optimise military personnel + athletes health and performance.
The almost instant blood test has the potential to become the first objective way to diagnose concussion. The device aims to end the need to have all head-knock victims sitting out on their duties, or competitions, without being sure of the extent of injury, or to quickly identify those suffering brain injuries so they can be safely cared for and managed. Currently, in the early proof-of-concept and prototyping stages, the device is awaiting tech validation by the CSIRO. The project has received funding via a grant from the Australian Department of Defence towards commercialisation.
About GLIA Diagnostics: Dedicated to researching + trialling novel biomarkers and companion technologies for the confirmation + prognosis of Traumatic Brain Injury (TBI).